Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
30 April 2024
|
|
18:58 | User:AED 4 changes history +85 [Alara E. Dagsali (4×)] | |||
|
|
18:58 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:47 (cur | prev) +22 Alara E. Dagsali talk contribs | ||||
|
|
18:28 (cur | prev) +20 Alara E. Dagsali talk contribs | ||||
|
|
18:15 (cur | prev) +23 Alara E. Dagsali talk contribs | ||||
|
|
N 18:58 | Isosulfan Blue 2 changes history +5,962 [Alara E. Dagsali (2×)] | |||
|
|
18:58 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:57 (cur | prev) +5,959 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Lymphazurin |aOrAn=a |indicationType=treatment |indication=Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therape...") | |||
|
|
N 18:47 | Ibuprofen Lysine 2 changes history +15,666 [Alara E. Dagsali (2×)] | |||
|
|
18:47 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:46 (cur | prev) +15,663 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=Ibuprofen lysine |aOrAn=a |indicationType=treatment |indication=Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conduc...") | |||
|
|
N 18:28 | Prussian blue 2 changes history +14,070 [Alara E. Dagsali (2×)] | |||
|
|
18:28 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:27 (cur | prev) +14,067 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |drugClass=RADIOGARDASE |indicationType=treatment |indication=Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination |adverseReactions=Most common adverse reaction (incidence >24%) was constipation Constipation was reported in 10 (24%) of 42 patients treated with R...") | |||
|
|
N 18:15 | Botulism Antitoxin 2 changes history +18,011 [Alara E. Dagsali (2×)] | |||
|
|
18:15 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
18:14 (cur | prev) +18,008 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=BAT |aOrAn=a |indicationType=treatment |indication=BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. |adverseReactions=The most common adverse reactions obse...") | |||
| m 15:35 | Medication reconciliation diffhist +1 Badgettrg talk contribs | ||||